Veeva Systems (VEEV) Q2 2027 earnings review
Veeva Accelerates Top Line Driven by CRM and R&D Execution, Raising Full-Year Targets
Veeva delivered an impressive 18% YoY total revenue growth in Q2, accelerating from the 16% growth seen in Q1. Broad strength across the business—particularly in the Vault CRM transition and R&D Cloud scaling—resulted in top-and-bottom-line beats. Non-GAAP Operating Income grew 18% YoY to $415.9M. Consequently, management raised FY27 revenue guidance to a midpoint of $3.684B (from ~$3.640B). The AI narrative is also rapidly materializing, with initial Veeva Falcon deployments on track for this year. However, investors should monitor the mix shift: Professional Services revenue is growing faster than high-margin subscriptions, applying subtle downward pressure to gross margins.
🐂 Bull Case
The massive platform migration away from Salesforce is succeeding. Veeva now has over 180 customers live on Vault CRM (up from 150+ in Q1) and secured 12 top 20 biopharma commitments globally, effectively de-risking a massive portion of its commercial revenue base.
The R&D and Quality solutions segment continues to be Veeva's primary growth engine. Subscription revenue from R&D surged 19.3% YoY, dwarfing Commercial's 13.0% growth, fueled by newer solutions like EDC and Safety (now surpassing 100 customers).
🐻 Bear Case
While total revenue growth is impressive, lower-margin Professional Services grew 24% YoY, heavily outpacing Subscription revenue growth of 16%. This mix shift compresses the structural margin ceiling in the near-term.
Veeva's legacy cash-cow, the Commercial Solutions segment, is stable but settling into lower double-digit growth (13%). Continued macroeconomic scrutiny on pharma digital ad spending (impacting Crossix) could pressure this segment further.
⚖️ Verdict: 🟢
Bullish. Veeva is flawlessly executing one of the highest-risk software transitions in recent enterprise history (Vault CRM migration) while successfully spinning up a massive secondary growth engine (R&D Cloud) and pioneering industry-specific AI (Falcon). The upwardly revised full-year guidance underscores structural strength despite a cloudy macro environment.
Key Themes
Vault CRM Transition De-Risked
Accelerating. The transition to Vault CRM is progressing exceptionally well. The company now boasts 180+ live customers and secured commitments from 12 of the top 20 biopharmas globally (securing 2 new top 20s and 1 large enterprise in August alone). Furthermore, they deployed Vault CRM and the Agentic Call Report across a full U.S. field team for a top 20 biopharma. This establishes deep structural moats against CRM competitors.
R&D and Quality Cloud Scaling Rapidly
Stable to Accelerating. Veeva R&D and Quality solutions remain the primary driver of subscription growth, compounding at 19.3% YoY in Q2. In the clinical space, a large enterprise biopharma added Veeva EDC to its existing eTMF/CTMS foundation. Safety Workbench scored a second top 20 biopharma win, pushing total Safety customers past 100. Quality added 30+ new customers across QualityDocs, QMS, and Training.
Agentic AI Transitions from Vision to Execution
Management's aggressive push into 'agentic labor' with Veeva Falcon is accelerating. Veeva acquired Copli in Q2 and immediately launched Veeva Falcon MLR to automate content reviews. Falcon for clinical, regulatory, and safety has secured 5 early adopters and is on track for initial go-lives this year, transitioning AI from a concept into a tangible workflow driver.
Professional Services Dragging on Margin Expansion
Reversing. A specific data point contradicting the 'flawless quarter' narrative is the structural gross margin. Non-GAAP Professional Services Gross Margin deteriorated from 33.4% in 26Q2 to 31.5% in 27Q2. Simultaneously, this lower-margin services segment grew much faster (24% YoY) than high-margin subscriptions (16% YoY). This mix shift resulted in total Non-GAAP Gross Margin contracting slightly from 77.5% in 26Q2 to 77.1% this quarter. Heavy implementations for CRM and R&D are pulling top-line growth but diluting software leverage.
Commercial Segment Growth Trailing R&D
Stable. The Commercial Solutions segment grew Subscription Revenue by 13% YoY to $347.4M. While healthy, it continues to meaningfully lag the 19.3% growth in R&D. Veeva's long-term dominance requires the Commercial segment (anchored by CRM and Crossix data) to maintain momentum against rising macroeconomic scrutiny of pharma digital advertising budgets.
Other KPIs
Accelerating. Net cash provided by operating activities for the first six months of FY27 jumped 22% YoY to $1,365.8M. Cash collections remain robust despite heavy CRM implementation schedules, pushing the total cash/short-term investment pile above $7.2 billion.
Stable. GAAP Subscription Cost of Revenue increased 12.6% YoY, visibly slower than the 16.3% growth in total Subscription Revenue. This demonstrates continued excellent structural scaling on the software infrastructure side, preserving an 86.2% GAAP subscription gross margin.
Guidance
Decelerating slightly. At the midpoint, this guidance implies a 15.1% YoY growth rate, which is a step down from the 17.6% growth delivered in the current Q2. This likely reflects typical seasonal lumpiness and a normalizing rate of implementations.
Accelerating vs prior guide. Management raised the full-year midpoint to ~$3.684B, up from the previously targeted ~$3.640B provided in Q1. This implies a 15.3% full-year growth rate over FY26.
Accelerating. Raised from previous guidance of ~$1,610 million. Implies a full-year Non-GAAP operating margin of 44.5%, proving that the company can absorb investments in AI (Falcon, Ostro, Copli) and the CRM rollout while preserving elite profitability.
Stable. Represents sequential flatness compared to the $2.35 delivered in Q2, but approximately 14.5% YoY growth over the $2.04 delivered in Q3 FY26.
Key Questions
M&A Impact on AI
Veeva acquired Copli in the quarter to launch Veeva Falcon MLR. How much of the raised full-year guidance is attributable to inorganic revenue from the Copli and Ostro acquisitions versus organic subscription growth?
Professional Services Mix Shift
Professional Services grew 24% YoY this quarter, driving overall revenue beats but putting pressure on total gross margins. When should investors expect Services growth to normalize closer to Subscription growth rates, alleviating this margin compression?
Top 20 CRM Outcomes
With 12 top 20 biopharmas now committed to Vault CRM (up from 10 previously), there are effectively only 2 decisions remaining among the 'undecided' top 20 cluster you highlighted previously. What is the status and timeline of these final anchor accounts?